Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Jinhui Dong, Seth J. Zost, Allison J. Greaney, et al.
Nature Microbiology (2021) Vol. 6, Iss. 10, pp. 1233-1244
Open Access | Times Cited: 310

Showing 1-25 of 310 citing articles:

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Yunlong Cao, Jing Wang, Fanchong Jian, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 657-663
Open Access | Times Cited: 1784
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1115
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. García-Beltrán, Kerri St. Denis, Angelique Hœlzemer, et al.
Cell (2022) Vol. 185, Iss. 3, pp. 457-466.e4
Open Access | Times Cited: 1032
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Aekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
Cell (2022) Vol. 185, Iss. 14, pp. 2422-2433.e13
Open Access | Times Cited: 677
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Jiahui Chen, Rui Wang, Nancy Benovich Gilby, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 2, pp. 412-422
Open Access | Times Cited: 644
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Myron J. Levin, Andrew Ustianowski, Stéphane De Wit, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 23, pp. 2188-2200
Open Access | Times Cited: 621
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen, et al.
Science (2022) Vol. 375, Iss. 6583, pp. 864-868
Open Access | Times Cited: 510
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Tyler N. Starr, Allison J. Greaney, Adam S. Dingens, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 4, pp. 100255-100255
Open Access | Times Cited: 496
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Wanwisa Dejnirattisai, Daming Zhou, Helen M. Ginn, et al.
Cell (2021) Vol. 184, Iss. 8, pp. 2183-2200.e22
Open Access | Times Cited: 398
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 373
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
Allison J. Greaney, Andrea N. Loes, Lauren E. Gentles, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 600
Open Access | Times Cited: 245
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 215
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
Richard Copin, Alina Baum, Elzbieta Wloga, et al.
Cell (2021) Vol. 184, Iss. 15, pp. 3949-3961.e11
Open Access | Times Cited: 213
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 206
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
Science (2022) Vol. 378, Iss. 6620, pp. 619-627
Open Access | Times Cited: 199
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Alexandra C. Walls, Marcos C. Miranda, Alexandra Schäfer, et al.
Cell (2021) Vol. 184, Iss. 21, pp. 5432-5447.e16
Open Access | Times Cited: 164
Antibodies to combat viral infections: development strategies and progress
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 158
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
Tongqing Zhou, Lingshu Wang, John Misasi, et al.
Science (2022) Vol. 376, Iss. 6591
Open Access | Times Cited: 153
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
Akatsuki Saito, Tomokazu Tamura, Jiří Zahradník, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 11, pp. 1540-1555.e15
Open Access | Times Cited: 152
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines
Suresh Thakur, Shalitha Sasi, Sindhu Gopinathan Pillai, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 141
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
James Brett Case, Samantha Mackin, John M. Errico, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 135
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Allison J. Greaney, Tyler N. Starr, Jesse D. Bloom
Virus Evolution (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 130
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
Daniele Focosi, Rodrigo Quiroga, Scott A. McConnell, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2264-2264
Open Access | Times Cited: 123
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 120
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 117
Page 1 - Next Page

Scroll to top